Influenza Clinical Trial
Official title:
Trivalent Influenza Vaccine in HIV-infected Pregnant Women and Kinetics of Transplacental Anti-influenza Antibody Transfer and Persistence in Young Infants: A Randomized Controlled Phase II Trial Evaluating Safety and Immunogenicity
This randomized, placebo controlled trial will evaluate the safety and immunogenicity of Trivalent Influenza Vaccine (TIV) in HIV-infected pregnant women, dynamics of transplacental anti-influenza antibody transfer to their newborns and kinetics thereof during early infancy.
Determining the contribution of influenza to early childhood morbidity and mortality in
sub-Saharan Africa and the potential to prevent influenza disease through vaccination may
contribute to reducing childhood deaths; since influenza illness is a vaccine preventable
disease for which vaccines are developed, licensed and available at reasonable cost.
Unfortunately, infants at highest risk for serious disease are those under 6 months of age,
for whom trivalent inactivated influenza vaccine (TIV) is poorly immunogenic and not
licensed. As pregnant women also have an increased risk of serious illness (3.3-5.5 fold for
hospitalization for influenza-associated acute cardio-respiratory illness) from influenza
infection, one strategy to prevent the complications of influenza in pregnant women and
young infants is through maternal TIV immunization, which is recommended by the WHO. This
could result in direct protection of the women and protection of the young infant consequent
to transplacental transfer of TIV induced antibody.
Barriers to administration of vaccines during pregnancy including lack of information on
effectiveness and concerns about safety probably explain the virtual non-existent use of TIV
in pregnant women from low-middle income countries, including South Africa.
The immunogenicity and efficacy of TIV in HIV-infected adults was only recently documented
in an African setting. A placebo-controlled, community-based randomized, placebo controlled
trial, conducted in South Africa reported that TIV was associated with a 75% reduction in
influenza-confirmed illness. The results of the study also confirmed the safety of TIV among
African HIV-infected adults. The study, however, only included 7 women who were pregnant. In
addition to no differences in solicited adverse event rates, there was also no difference in
either CD4+ cell count changes or HIV viral control in those on antiretroviral treatment
between TIV vaccinees compared to placebo recipients. This allayed previous concerns
regarding the potential negative effect of TIV which centered around the observed transient
increase in HIV-1 viral load, even in HIV infected individuals on ART and who were
virologically suppressed (viral load <400 copies/ml). Decreases in CD4+ lymphocyte counts
have also been observed in HIV-infected individuals post TIV vaccination. These changes,
however, even in past studies were infrequent (4-18%) and resolved at later time-points and
were considered to be clinically non-significant.
Only recently has data become available from Bangladesh in which the benefit of maternal TIV
vaccination was demonstrated by a 63% (95%CI 5 to 85) reduction in laboratory-confirmed
influenza illness in infants under 24 weeks of age in children born to mothers vaccinated
with TIV and a 36% reduction in clinical illness in vaccinated mothers. There has, however,
not been any study on the effectiveness of maternal immunization with TIV on influenza-
associated morbidity and mortality either in the mothers or infants in African settings.
Despite the encouraging results on maternal immunization from Bangladesh, and the
preliminary data supporting that TIV is efficacious mainly in HIV-infected non-pregnant
adults, further data are needed to advocate for routine use of TIV during pregnancy in
settings with a high prevalence of HIV. Reasons for this include that the impact of maternal
HIV on the kinetics of TIV induced transplacental antibody transfer cannot be derived from
available data. This is important as the primary focus of this proposal, and major potential
public health benefit of maternal TIV vaccination, is targeted at protection of young
infants. HIV infection is known to decrease placental integrity and lower antibody levels in
the fetus and newborn. Furthermore, maternal hypergamma-globulinemia that is characteristic
of HIV-infection may be associated with decreased neonatal antibody levels. This paradox is
explained by the limited number of placental antibody receptors, resulting in IgG antibodies
competing for available receptors and thereby decreasing vaccine-specific antibody
transport. Preterm birth increases with HIV, chronic maternal disease or malnutrition.
Transfer of maternal antibody which is gestational age dependant, may be more affected by
maternal immunization in sub-Saharan Africa where these conditions are common.
The overall aim of this project is to evaluate the safety and immunogenicity of TIV
vaccination of HIV-infected pregnant women
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |